FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2072109395> ?p ?o ?g. }

• W2072109395 endingPage "608" @default.
• W2072109395 startingPage "602" @default.
• W2072109395 abstract "Platelet activation has been reported to occur in patients with Raynaud's phenomenon; however, the effect of calcium channel blockers and thromboxane synthetase inhibitors has not been prevlously studied. The effect of two drugs that potentially inhibit platelet activation were studied: nlfedipine, a calcium channel blocker, and dazoxiben, a specific thromboxane synthetase Inhibitor. Two platelet-specific proteins released during platelet activation, betathromboglobulin and platelet factor 4, were measured during a double-blind clinical trial of these two drugs In patients with Raynaud's phenomenon. The plasma beta-thromboglobulin level was significantly elevated In the patient population (53.8 ± 7.6 ng/ml) during the, placebo period compared with that in a normal control population (27.0 ± 3.1 ng/ml) (p <0.01). The plasma platelet factor 4 level was 8.7 ± 2.2 ng/ml in the patients compared with 6.5 ± 1.0 ng/ml in the normal subjects (p = NS). These findings indicate the presence of In vivo platelet activation in patients with Raynaud's phenomenon. Nifedipine lowered the levels of beta-thromboglobulin to near the normal range (33.4 ± 4.6 ng/ml). The inhibition of platelet activation by nifedipine was associated with clinical improvement in Raynaud's phenomenon with fewer and less intense episodes. Beta-thromboglobulin was not lowered by dazoxiben (58.1 ± 9.0 ng/ml) compared with the placebo. The reduction of beta-thromboglobulin levels by nifedipine Indicates that In vivo platelet activation was inhibited by this agent. Since this was associated with a reduced frequency of attacks, It is not clear whether this was a direct effect of the drug on platelet activation, leading to decreased frequency of vasospasm, or an effect on vascular smooth muscle leading to decreased vasospasm and a secondary decrease in platelet activation." @default.
• W2072109395 created "2016-06-24" @default.
• W2072109395 creator A5001423962 @default.
• W2072109395 creator A5015533049 @default.
• W2072109395 creator A5048374080 @default.
• W2072109395 creator A5068528030 @default.
• W2072109395 date "1985-04-01" @default.
• W2072109395 modified "2023-09-27" @default.
• W2072109395 title "Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation" @default.
• W2072109395 cites W1964475631 @default.
• W2072109395 cites W1969559107 @default.
• W2072109395 cites W1971654302 @default.
• W2072109395 cites W1972631110 @default.
• W2072109395 cites W1980581864 @default.
• W2072109395 cites W1980896739 @default.
• W2072109395 cites W1996578461 @default.
• W2072109395 cites W1999701858 @default.
• W2072109395 cites W2000706210 @default.
• W2072109395 cites W2035405003 @default.
• W2072109395 cites W2039330939 @default.
• W2072109395 cites W2043834136 @default.
• W2072109395 cites W2050921272 @default.
• W2072109395 cites W2053806685 @default.
• W2072109395 cites W2054604454 @default.
• W2072109395 cites W2056818332 @default.
• W2072109395 cites W2070690398 @default.
• W2072109395 cites W2077768088 @default.
• W2072109395 cites W2084764718 @default.
• W2072109395 cites W2090866746 @default.
• W2072109395 cites W2102209048 @default.
• W2072109395 cites W2109517079 @default.
• W2072109395 cites W2149568156 @default.
• W2072109395 cites W2163402335 @default.
• W2072109395 cites W2167603656 @default.
• W2072109395 cites W2316102942 @default.
• W2072109395 cites W2340410345 @default.
• W2072109395 cites W2377108921 @default.
• W2072109395 cites W2399917094 @default.
• W2072109395 cites W2406725816 @default.
• W2072109395 cites W2410725554 @default.
• W2072109395 cites W2884438207 @default.
• W2072109395 cites W3113058496 @default.
• W2072109395 cites W45316589 @default.
• W2072109395 cites W2115941361 @default.
• W2072109395 doi "https://doi.org/10.1016/0002-9343(85)90402-4" @default.
• W2072109395 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/3157318" @default.
• W2072109395 hasPublicationYear "1985" @default.
• W2072109395 type Work @default.
• W2072109395 sameAs 2072109395 @default.
• W2072109395 citedByCount "56" @default.
• W2072109395 countsByYear W20721093952012 @default.
• W2072109395 countsByYear W20721093952013 @default.
• W2072109395 countsByYear W20721093952014 @default.
• W2072109395 countsByYear W20721093952016 @default.
• W2072109395 countsByYear W20721093952017 @default.
• W2072109395 countsByYear W20721093952021 @default.
• W2072109395 crossrefType "journal-article" @default.
• W2072109395 hasAuthorship W2072109395A5001423962 @default.
• W2072109395 hasAuthorship W2072109395A5015533049 @default.
• W2072109395 hasAuthorship W2072109395A5048374080 @default.
• W2072109395 hasAuthorship W2072109395A5068528030 @default.
• W2072109395 hasConcept C126322002 @default.
• W2072109395 hasConcept C134018914 @default.
• W2072109395 hasConcept C142724271 @default.
• W2072109395 hasConcept C159973064 @default.
• W2072109395 hasConcept C204787440 @default.
• W2072109395 hasConcept C27081682 @default.
• W2072109395 hasConcept C2776785769 @default.
• W2072109395 hasConcept C2779066535 @default.
• W2072109395 hasConcept C2908647359 @default.
• W2072109395 hasConcept C3018697912 @default.
• W2072109395 hasConcept C519063684 @default.
• W2072109395 hasConcept C71924100 @default.
• W2072109395 hasConcept C89560881 @default.
• W2072109395 hasConcept C98274493 @default.
• W2072109395 hasConcept C99454951 @default.
• W2072109395 hasConceptScore W2072109395C126322002 @default.
• W2072109395 hasConceptScore W2072109395C134018914 @default.
• W2072109395 hasConceptScore W2072109395C142724271 @default.
• W2072109395 hasConceptScore W2072109395C159973064 @default.
• W2072109395 hasConceptScore W2072109395C204787440 @default.
• W2072109395 hasConceptScore W2072109395C27081682 @default.
• W2072109395 hasConceptScore W2072109395C2776785769 @default.
• W2072109395 hasConceptScore W2072109395C2779066535 @default.
• W2072109395 hasConceptScore W2072109395C2908647359 @default.
• W2072109395 hasConceptScore W2072109395C3018697912 @default.
• W2072109395 hasConceptScore W2072109395C519063684 @default.
• W2072109395 hasConceptScore W2072109395C71924100 @default.
• W2072109395 hasConceptScore W2072109395C89560881 @default.
• W2072109395 hasConceptScore W2072109395C98274493 @default.
• W2072109395 hasConceptScore W2072109395C99454951 @default.
• W2072109395 hasIssue "4" @default.
• W2072109395 hasLocation W20721093951 @default.
• W2072109395 hasLocation W20721093952 @default.
• W2072109395 hasOpenAccess W2072109395 @default.
• W2072109395 hasPrimaryLocation W20721093951 @default.
• W2072109395 hasRelatedWork W2003842308 @default.
• W2072109395 hasRelatedWork W2011451727 @default.

• next